Akebia's $41M Cash Infusion Boosts Anemia Drug Work
By Catherine Shaffer
Wednesday, June 5, 2013
A bit more than a year after handing in positive results in a Phase II study for AKB-6548 in chronic kidney disease (CKD), Akebia Therapeutics Inc., of Cincinnati, secured a $41 million Series C financing to fund ongoing development of the drug.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.